Vis-nol capsules 120mg 30 pcs.

Pharmacodynamics. has a gastroprotective effect. in the acidic environment of the stomach, colloidal bismuth subcitrate forms a protective film on the surface of ulcers and erosions, which promotes their scarring and protects the mucous membrane from the effects of gastric juice. the drug stimulates the synthesis of prostaglandin e2, increases the formation of mucin and secretion of bicarbonate, leads to the accumulation of epidermal growth factor in the defect zone, reduces the activity of pepsin and pepsinogen.

The drug has antimicrobial activity against Helicobacter pylori.

Pharmacokinetics. Colloidal bismuth subcitrate is practically not absorbed in the gastrointestinal tract, only a small amount of the active substance enters the blood and is excreted in the urine, while the concentration of bismuth in the blood plasma after the end of treatment decreases rapidly. It is excreted mainly with feces.

• Gastric and duodenal ulcer, including those caused by Helicobacter pylori (as part of anti-Helicobacter therapy regimens); chronic gastritis and gastroduodenitis in the acute phase, including those caused by Helicobacter pylori;

Take orally with a small amount of water.

Adults and children over 14 years of age should take 1 capsule 4 times a day 30 minutes before meals and at night or 2 capsules 2 times a day.

Children aged 8 to 14 years should be prescribed 1 capsule 2 times a day 30 minutes before meals.

Children aged 4 to 8 years should be prescribed a dose of 8 mg/kg/day, dividing the daily dose into 2 doses, but not more than 2 capsules per day.

The duration of the treatment course is 4-8 weeks. During 8 weeks, you should not take drugs containing bismuth.

In the presence of Helicobacter pylori, use Vis-Nol in anti-helicobacter therapy regimens as prescribed by a doctor. In quadruple therapy, it is recommended to combine Vis-Nol 120 mg 4 times a day with tetracycline 500 mg 4 times a day, metronidazole 500 mg 3 times a day and a proton pump inhibitor (omeprazole, lansoprazole, pantoprazole or esomeprazole) in a standard therapeutic dose 2 times a day. The duration of combination therapy is 10-14 days.

To improve the regeneration of the ulcer defect, further treatment with Vis-Nol is possible: 1 capsule 4 times a day 30 minutes before breakfast, lunch and dinner, the 4th time – before bedtime. The total duration of therapy with Vis-Nol is up to 6 weeks (maximum 8 weeks).

Hypersensitivity to the components of the drug, severe renal failure.

Gastrointestinal tract: black stools, nausea, vomiting, constipation, diarrhea;

Skin and subcutaneous tissue disorders: rash, itching;

Immune system: anaphylactic reactions.

When using the drug, the stool may turn black. In this case, you should consult a doctor.

You should not take antacids or drink milk half an hour before and half an hour after taking the drug, as the available gastric juice is needed to form a protective layer.

Long-term use of bismuth compounds is not recommended due to the occurrence of encephalopathy in isolated cases. If the recommended regimen is followed, the risk of this side effect is very low. However, it is not recommended to take other drugs containing bismuth while taking Vis-Nol.

The medicine contains the dye sunset yellow FCF (E110), which may cause allergic reactions.

Use during pregnancy and breastfeeding. Not recommended.

Children. Vis-Nol should be used in children from 4 years of age.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. There is no data on the effect of Vis-Nol on the reaction rate. However, such an effect of the drug is unlikely.

No other medicines, food or drinks, antacids, milk, fruit or fruit juices should be taken half an hour before or after taking Vis-Nol, as they may change its effect.

Reduces the absorption of tetracycline; simultaneous use of drugs containing bismuth increases the risk of excessive increase in the concentration of bismuth in the blood.

With frequent use of the drug in high doses, overdose is possible, which may manifest itself after 10 days with symptoms characteristic of renal failure (increased levels of bismuth in blood plasma).

In case of impaired renal function, accompanied by a high content of bismuth in the blood plasma, complexing compounds should be used – dimercaptosuccinic and dimercaptopropanesulfonic acids.

Treatment consists of gastric lavage followed by administration of activated charcoal and osmotic laxatives. Bismuth absorption as an additional treatment is optional. In case of concomitant severe kidney diseases, hemodialysis should be performed.

In the original packaging at a temperature not exceeding 25 °C.